105 related articles for article (PubMed ID: 7685368)
1. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.
Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G
J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
3. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
Antonelli G; Currenti M; Turriziani O; Dianzani F
J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335
[TBL] [Abstract][Full Text] [Related]
5. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients.
Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L
J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.
Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G
Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526
[TBL] [Abstract][Full Text] [Related]
7. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha.
Jorns C; Holzinger D; Thimme R; Spangenberg HC; Weidmann M; Rasenack J; Blum HE; Haller O; Kochs G
J Med Virol; 2006 Jan; 78(1):74-82. PubMed ID: 16299717
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial.
Diodati G; Bonetti P; Noventa F; Casarin C; Rugge M; Scaccabarozzi S; Tagger A; Pollice L; Tremolada F; Davite C
Hepatology; 1994 Jan; 19(1):1-5. PubMed ID: 7506223
[TBL] [Abstract][Full Text] [Related]
9. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
[TBL] [Abstract][Full Text] [Related]
10. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
11. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2.
Nolte KU; Günther G; von Wussow P
Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261
[TBL] [Abstract][Full Text] [Related]
12. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies.
Viscomi GC; Antonelli G; Bruno C; Scapol L; Malavasi F; Funaro A; Simeoni E; Pestka S; De Pisa F; Dianzani F
J Interferon Cytokine Res; 1999 Apr; 19(4):319-26. PubMed ID: 10334382
[TBL] [Abstract][Full Text] [Related]
13. Successful re-treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid interferon-alpha N1 and in vitro studies on the specificity of the antibodies.
Brand CM; Leadbeater L; Budiman R; Lechner K; Gisslinger H
Br J Haematol; 1994 Jan; 86(1):216-8. PubMed ID: 8011536
[TBL] [Abstract][Full Text] [Related]
14. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.
Scagnolari C; Casato M; Bellomi F; De Pisa F; Turriziani O; Coviello R; Pirro MR; Dianzani F; Antonelli G
Clin Diagn Lab Immunol; 2003 Jan; 10(1):70-7. PubMed ID: 12522042
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
16. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.
Milella M; Antonelli G; Santantonio T; Giannelli G; Currenti M; Monno L; Turriziani O; Pastore G; Dianzani F
Hepatogastroenterology; 1995 Jul; 42(3):201-4. PubMed ID: 7590565
[TBL] [Abstract][Full Text] [Related]
17. IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a.
Ross C; Engler CB; Sander B; Bendtzen K
J Interferon Cytokine Res; 2002 Apr; 22(4):421-6. PubMed ID: 12034024
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of antibodies to hepatitis C virus during interferon-alpha therapy.
Yuki N; Hayashi N; Hagiwara H; Takehara T; Katayama K; Kasahara A; Fusamoto H; Kamada T
Hepatology; 1993 Jun; 17(6):960-5. PubMed ID: 7685734
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of antibody to Y19 protein in nonA and nonB chronic liver disease].
Sakashita H
Fukuoka Igaku Zasshi; 1993 Apr; 84(4):159-72. PubMed ID: 7686128
[TBL] [Abstract][Full Text] [Related]
20. The interferon-alpha 2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-alpha 2a.
Hosoi H; Imai M; Yamanaka M
J Gastroenterol Hepatol; 1992; 7(4):411-6. PubMed ID: 1515568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]